Daily Cardiology Research Analysis
Analyzed 92 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies span basic-to-population science: (1) an integrated human–animal–omics investigation reveals an NAD+ salvage deficit in valvular endothelial cells as a driver of calcific aortic valve disease and shows early nicotinamide mononucleotide therapy attenuates calcification; (2) a multi-stage, multiethnic metabolomics program identifies circulating gut microbial metabolites that predict incident coronary heart disease; and (3) VEGF-C–driven cardiac lymphangiogenesis in murine autoimmune myocarditis resolves inflammation and preserves function, nominating the lymphatic network as a therapeutic target.
Research Themes
- Valvular calcification and endothelial NAD+ metabolism
- Gut microbiome-derived metabolites as CHD risk biomarkers
- Therapeutic lymphangiogenesis in inflammatory myocarditis
Selected Articles
1. Senescence-associated metabolic alterations aggravate calcific aortic valve disease.
Integrated human–animal–omics evidence identifies endothelial NAD+ salvage failure (via NAMPT suppression) as an initiator of calcific aortic valve disease, amplified by macrophage-derived extracellular NAMPT signaling. Early nicotinamide mononucleotide restored NAD+, reduced inflammatory signaling and macrophage infiltration, and attenuated calcification, whereas delayed therapy was less effective.
Impact: This work delineates a cell-compartmentalized NAD+ circuit that mechanistically links inflammaging to valvular calcification and demonstrates time-sensitive metabolic rescue. It nominates NAMPT/NAD+ pathways and early NAD+ repletion as druggable strategies in a disease with no proven pharmacotherapy.
Clinical Implications: Although preclinical, the data support prioritizing early metabolic interventions (e.g., NAD+ repletion strategies) and biomarker-guided risk stratification (circulating NAMPT) in calcific aortic valve disease; clinical trials should evaluate timing and patient selection.
Key Findings
- Valvular endothelial NAMPT suppression depletes NAD+, inactivates SIRT1, hyper-acetylates NF-κB, and induces an ICAM-1–rich inflammaging phenotype.
- Recruited macrophages upregulate NAMPT and secrete extracellular NAMPT that signals via TLR4 on endothelial cells, amplifying inflammation.
- Mendelian randomization links elevated plasma NAMPT to increased aortic stenosis risk.
- Early nicotinamide mononucleotide therapy restores valvular NAD+, reduces inflammation and macrophage infiltration, and attenuates calcification; delayed therapy is less effective.
Methodological Strengths
- Multi-layered translational design integrating human bulk and single-cell transcriptomics, murine genetic models, and UK Biobank proteomics/MR.
- Temporal therapeutic testing (early vs late NMN) to probe causality and timing effects.
Limitations
- Preclinical therapeutic evidence; no randomized human interventional data.
- Exact human sample sizes and external validation cohorts for biomarkers beyond UK Biobank are not detailed in the abstract.
Future Directions: Conduct phase 1/2 trials of NAD+ repletion (e.g., NMN) with biomarker enrichment and explore NAMPT-targeted strategies; validate circulating NAMPT as a prognostic/theranostic in calcific aortic valve disease.
BACKGROUND AND AIMS: Calcific aortic valve disease lacks effective pharmacotherapy and is tightly linked to ageing. Since nicotinamide adenine dinucleotide (NAD+) steadily declines with age, this study investigated whether cell-type-specific disruption of NAD+ salvage metabolism drives valvular inflammation and calcification. METHODS: This study combined integrated human aortic-valve bulk RNA-seq with single-cell transcriptomics to map NAD+ pathways. Effects of nicotinamide phosphoribosyltransferase (NAMPT) loss or gain were tested in heterozygous, endothelial-specific, and myeloid-specific Nampt-knockout mice and in cultured valvular endothelial cells and macrophages. Therapeutic potential was evaluated with early vs late nicotinamide mononucleotide supplementation. UK Biobank proteomics and Mendelian randomization examined associations between circulating NAMPT and aortic stenosis. RESULTS: In aged human valves, NAMPT-mediated salvage exhibited the steepest suppression within valvular endothelial cells, triggering NAD+ depletion, SIRT1 inactivation, and hyper-acetylated nuclear factor kappa-B, thereby resulting in an ICAM-1-rich inflammaging profile. Recruited macrophages displayed paradoxical NAMPT up-regulation and secreted extracellular NAMPT that signalled through TLR4 on endothelial cells, amplifying valvular inflammation. Genomic analyses revealed that elevated plasma NAMPT conferred a higher risk of aortic stenosis. On the other side, myeloid Nampt deletion generated a senescent phenotype marked by FOXA2 acetylation and MMP13-driven collagen disruption, accelerating leaflet calcification. Early nicotinamide mononucleotide therapy restored valvular NAD+, dampened endothelial inflammation, limited macrophage infiltration, and attenuated calcification, while delayed treatment was less effective. CONCLUSIONS: Calcific aortic valve disease is initiated by endothelial NAD+ insufficiency and magnified by metabolically diverse macrophages. This compartmentalized NAD+ circuit couples inflammaging to matrix catastrophe. Early NAD+ repletion via nicotinamide mononucleotide and interventions targeting NAMPT warrant clinical evaluation as potential therapies for calcific aortic valve disease.
2. Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study.
Across five prospective cohorts and multiple validation stages, several circulating gut microbiome–derived metabolites (e.g., imidazole propionate, TMAO, phenylacetyl-L-glutamine) were consistently associated with incident CHD with adjusted ORs per SD of ~1.18–1.27. Associations were generally robust across subgroups, underscoring gut microbial metabolism as a modifiable risk axis and nominating candidate biomarkers and targets.
Impact: This multiethnic, multi-stage program moves beyond single-metabolite reports by discovering, validating, and quantifying microbial metabolites prospectively associated with incident CHD, enabling translational pipelines for biomarkers and interventions.
Clinical Implications: Risk prediction may be enhanced by incorporating validated microbial metabolites; findings support mechanistic trials (e.g., diet, pre/probiotics, enzyme inhibition) to modulate culprit pathways such as TMAO and phenylacetyl-L-glutamine.
Key Findings
- Discovery in nested case-control sets (896 cases/896 controls) identified 73 microbiota-related metabolites associated with incident CHD (FDR<0.10).
- In-silico validation in ARIC (N=3,539; 663 cases) and MESA (N=3,860; 446 cases) confirmed 24 associations in the same direction.
- Targeted assays quantified and confirmed risk associations for nine metabolites, including imidazole propionate, TMAO, phenylacetyl-L-glutamine (OR per SD ~1.18–1.27).
- Associations were broadly consistent across demographic and clinical subgroups, with some effect modification by race, age, obesity, and follow-up time.
Methodological Strengths
- Prospective, multi-stage design with discovery, in-silico validation, and targeted quantification across diverse cohorts.
- Robust multivariable adjustment with harmonized covariates; subgroup and sensitivity analyses.
Limitations
- Observational design cannot prove causality; residual confounding is possible.
- Not all significant discovery metabolites were validated/quantified due to platform coverage differences.
Future Directions: Prioritize mechanistic studies and randomized dietary/microbiome-targeted interventions modulating validated metabolites; evaluate additive value in CHD risk prediction models.
BACKGROUND: Despite growing evidence linking gut microbiota and microbial metabolites to human cardiometabolic health, few studies have systematically examined associations between circulating microbial metabolites and incident coronary heart disease (CHD). METHODS AND FINDINGS: We conducted a multi-stage metabolomics study involving five prospective cohorts. Discovery involved untargeted plasma metabolite profiling of 896 incident cases and 896 age-/sex-/race-matched controls (~300 pairs per race: Black, White, Asian) from the Southern Community Cohort Study (SCCS; baseline: 2002-2009) and the Shanghai Women's Health Study and Shanghai Men's Health Study (SWHS/SMHS; baseline: 1996-2000 and 2002-2006). In-silico validation was conducted in the Atherosclerosis Risk in Communities Study (ARIC; N = 3,539; 663 cases; baseline: 1987-1989) and Multi-Ethnic Study of Atherosclerosis (MESA; N = 3,860; 446 cases; baseline: 2000-2002). Lastly, a quantitative assay was developed and applied to a new set of 864 cases and 864 age-/sex-/race-matched controls (~260-340 pairs per race) from the SCCS and SWHS/SMHS. Conditional logistic regression estimated odds ratios (ORs) of incident CHD per standard deviation (SD) metabolite increase in discovery and quantitative stages with a nested case-control design. Cox regression was used in ARIC and MESA with a cohort design. Similar covariates were adjusted across stages, including age, sex (if applicable), race (if applicable), education, income, smoking status, alcohol consumption, physical activity, diet quality, and body mass index (BMI). The mean (SD) time between enrollment and CHD diagnosis was 5.6 (3.8), 6.9 (4.4), 15.0 (7.4), and 8.0 (4.9) years in the SCCS, SWHS/SMHS, ARIC, and MESA, respectively. The discovery stage identified 73 circulating microbiota-related metabolites associated with incident CHD (false discovery rate <0.10). Sixty-one metabolites were available for in-silico validation, of which 24 showed a significant association (p < 0.05) in the same direction as in the discovery. The targeted assay quantified eight of the 24 metabolites, with five significantly associated with incident CHD: imidazole propionate, 3-hydroxy-2-ethylpropionate, 4-hydroxyphenylacetate, trans-4-hydroxyproline, and 3-hydroxybutyrate; OR per SD ranged from 1.18 to 1.27 after adjustment for sociodemographics, lifestyles, and BMI. The targeted assay measured eight other promising microbial metabolites, four of which were significant: trimethylamine N-oxide, phenylacetyl-L-glutamine, 4-hydroxyhippuric acid, and indolepropionate. Most associations were consistent across participant subgroups by demographics, lifestyles, metabolic disease history, family CHD history, and follow-up time, although some potential effect modifications were found by race, age, obesity status, and follow-up time. The main limitations of the study are the observational design and the inability to validate all significant metabolites due to differences in metabolomic assay coverage across the three stages. CONCLUSIONS: We identified and validated circulating gut microbial metabolites associated with incident CHD across diverse populations. Our findings offer novel epidemiological evidence on the importance of gut microbial metabolism in CHD development and highlight specific metabolites to prioritize for mechanistic investigation, biomarker validation, and therapeutic development.
3. VEGF-C-mediated cardiac lymphangiogenesis promotes inflammation resolution in autoimmune acute myocarditis in mice.
In murine autoimmune myocarditis, VEGF-C (VEGFR3 agonist) enhanced cardiac lymphangiogenesis, reduced edema, immune infiltration, and interstitial fibrosis, and preserved systolic function. It selectively diminished iNOS+ inflammatory macrophages without broadly suppressing T cells, marking the lymphatic network as a modifiable, immunoregulatory therapeutic target.
Impact: This study uncovers a tractable immunoregulatory compartment—the cardiac lymphatic system—in myocarditis and demonstrates disease modification via VEGFR3-directed lymphangiogenesis, opening a new therapeutic avenue in inflammatory cardiomyopathies.
Clinical Implications: While preclinical, findings support clinical translation of VEGFR3-agonist lymphangiogenic therapies and imaging biomarkers of cardiac lymphatics to stratify and monitor myocarditis patients.
Key Findings
- VEGF-C C156S enhanced cardiac lymphatic sprouting and function, reducing myocardial water content (edema).
- Immune cell infiltration and interstitial fibrosis were attenuated, with preservation of echocardiographic cardiac function.
- Selective reduction of iNOS+ inflammatory macrophages occurred without broad suppression of T cells or reparative macrophages.
- Transcriptomics confirmed down-regulation of macrophage activation–linked inflammatory programs; human autopsy hearts showed lymphatic expansion.
Methodological Strengths
- Use of a validated murine EAM model with multimodal phenotyping (histology, echocardiography, qPCR, RNA-seq).
- Inclusion of human autopsy tissue to enhance translational relevance.
Limitations
- Preclinical model; lack of randomized human trials assessing VEGF-C/VEGFR3 agonists.
- Safety, dosing, and off-target effects of lymphangiogenic therapy remain to be defined clinically.
Future Directions: Develop noninvasive imaging of cardiac lymphatics; test VEGFR3-directed therapies in large animals and early-phase human studies; define biomarkers predicting response.
AIMS: Acute myocarditis is an immune-mediated inflammatory disease characterized by myocardial inflammation and edema. Although cardiac lymphatic vessels are essential for fluid clearance and immune regulation, their role in modulating autoimmune cardiac inflammation remains largely undefined. We aimed to determine whether promoting lymphangiogenesis could mitigate inflammation and preserve cardiac function in autoimmune myocarditis. METHODS AND RESULTS: We used a murine model of experimental autoimmune myocarditis (EAM) induced by cardiac myosin peptide immunization and examined human autopsy hearts for lymphatic expansion. Mice received VEGF-C C156S, a VEGFR3-selective agonist, starting one week after immunization. We assessed lymphangiogenesis, edema, immune infiltration, fibrosis, and cardiac function using immunohistochemistry, echocardiography, qPCR, and RNA sequencing. VEGF-C treatment enhanced lymphatic sprouting and function, reduced myocardial water content, and attenuated immune cell infiltration and interstitial fibrosis. Cardiac function was preserved, as measured by echocardiography. Notably, VEGF-C selectively decreased the accumulation of iNOS+ inflammatory macrophages without broadly suppressing T cells or reparative macrophage subsets. Transcriptomic profiling confirmed down-regulation of inflammatory gene programs associated with macrophage activation. CONCLUSIONS: Early stimulation of cardiac lymphangiogenesis by VEGF-C promotes inflammation resolution, limits myocardial injury, and preserves cardiac function in autoimmune myocarditis. Targeting the cardiac lymphatic system may represent a novel therapeutic strategy for inflammatory heart disease. TRANSLATIONAL PERSPECTIVE: This study identifies the cardiac lymphatic network as a modifiable immunoregulatory compartment in myocarditis. Therapeutic lymphangiogenesis via VEGF-C not only improves lymphatic drainage but also selectively modulates inflammatory macrophage subsets, leading to improved cardiac outcomes. These findings support VEGFR3-directed lymphangiogenic stimulation as a promising treatment for autoimmune and inflammatory cardiomyopathies that currently lack effective disease-modifying therapies.